GlassScriptPhysician profile
Cindy Chapman
NPI 1104410968
$2,987.04
in general payments reported to CMS, 2019-2025
27 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $532 · 2023: $595 · 2024: $444 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245 · Education: $15.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.70 |
| Education | $15.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $830.65 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $397.40 | 2021-2025 | Farxiga |
| Amgen INC. | $207.46 | 2023-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $193.28 | 2021-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $174.99 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Novo Nordisk INC | $141.99 | 2023-2025 | Ozempic |
| Travere Therapeutics, INC. | $136.92 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.73 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $125.51 | 2025 | |
| Calliditas Therapeutics US INC. | $99.14 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.42 | 2022 | |
| Vifor Pharma, INC. | $71.05 | 2022-2023 | Veltassa |
| Akebia Therapeutics INC | $44.35 | 2022-2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $43.30 | 2022-2023 | Gattex |
| Lilly USA, LLC | $32.54 | 2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $30.75 | 2025 | Defencath |
| Opko Pharmaceuticals, LLC | $29.93 | 2021-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $29.01 | 2021-2022 | |
| Scpharmaceuticals INC. | $24.97 | 2025 | |
| Apellis Pharmaceuticals, INC. | $24.95 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.32 | 2024 | |
| Kyowa Kirin, INC. | $20.54 | 2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $20.44 | 2024 | Lupkynis |
| Genentech USA, INC. | $20.22 | 2025 | |
| Nxstage Medical, INC. | $19.46 | 2025 | Nxstage System One, Liberty Select Cycler |
| Alexion Pharmaceuticals, INC. | $17.26 | 2021 | |
| Shield Therapeutics INC | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.